(Q42234413)

19 October 2017

0 references

A direct and indirect comparison meta-analysis on the efficacy of cytomegalovirus preventive strategies in solid organ transplant (English)

1 reference

19 October 2017

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24385444%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

Diana F Florescu

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24385444%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Fang Qiu

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24385444%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Andre C Kalil

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24385444%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

language of work or name

English

0 references

publication date

2 January 2014

1 reference

Clinical Infectious Diseases

19 October 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24385444%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

volume

58

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24385444%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24385444%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

page(s)

785-803

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24385444%20AND%20SRC:MED&resulttype=core&format=json

Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients

13 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Preemptive therapy versus valgancyclovir prophylaxis in cytomegalovirus-positive kidney transplant recipients receiving antithymocyte globulin induction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Can preemptive cytomegalovirus monitoring be as effective as universal prophylaxis when implemented as the standard of care in patients at moderate risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Preemptive therapy is not adequate for prevention of cytomegalovirus disease in pancreas-kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Preemptive therapy for the prevention of cytomegalovirus disease in renal transplant recipients: our preliminary experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Preemptive therapy with intravenous ganciclovir for the prevention of cytomegalovirus disease in lung transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Pre-emptive intravenous ganciclovir versus valganciclovir prophylaxis for de novo cytomegalovirus-seropositive kidney-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Pre-emptive oral ganciclovir can reduce the risk of cytomegalovirus disease in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Cytomegalovirus pp65 antigen-guided preemptive therapy with ganciclovir in solid organ transplant recipients: a prospective, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: a multicenter, open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Cytomegalovirus (CMV) prophylaxis by acyclovir in pre-transplant CMV-positive renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Preemptive versus prophylactic protocol to prevent cytomegalovirus infection after renal transplantation: a meta-analysis and systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Interlaboratory comparison of cytomegalovirus viral load assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Interpreting quantitative cytomegalovirus DNA testing: understanding the laboratory perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Crystal structure of human cytomegalovirus IL-10 bound to soluble human IL-10R1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Role of cytomegalovirus infection in allograft rejection: a review of possible mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Cytomegalovirus-infected human endothelial cells can stimulate allogeneic CD4+ memory T cells by releasing antigenic exosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945

Leukopenia Complicates Cytomegalovirus Prevention After Renal Transplantation With Alemtuzumab Induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT945